INVESTORS & MEDIA

These slides contain the 48-week data from the Phase 2/3 PHOTON study (by Dr. David M. Brown) and the Phase 3 PULSAR study (by Jean-François Korobelnik) of aflibercept 8 mg for DME and nAMD, respectively, as presented at the 55th Annual Scientific Session of The Retina Society on November 3-4, 2022.

These slides contain the 48-week results from the Phase 2/3 PHOTON study (by Dr. David M. Brown) and the Phase 3 PULSAR study (by Dr. Paolo Lanzetta) of aflibercept 8 mg for DME and nAMD, respectively, as presented at AAO 2022 on September 30, 2022.

These slides contain the Ph2 CANDELA data through week 44. The full CANDELA presentation was given by Dr. David M. Brown at Angiogenesis, Exudation, and Degeneration 2022 on February 12, 2022.

Due to continuing concerns regarding the COVID-19 pandemic and to assist in protecting the health and well-being of our shareholders, directors, and employees, we have opted to hold the Annual Meeting as a virtual-only meeting. Shareholders will be able to attend the Annual Meeting and participate electronically, which will allow them to vote their shares on the date of the Annual Meeting and ask questions during the meeting. Under New York law, the legal requirement to include an in-person option has been waived by relevant governmental action.

We strongly encourage shareholders to visit this website for the most up-to-date information on the Annual Meeting.

Dial-In Number: (888) 660-6127 (U.S.)
(973) 890-8355: (International)
Conference ID: 7569618”